Novartis Healthcare

Novartis is a leading global pharmaceutical company headquartered in Basel, Switzerland, dedicated to developing innovative medicines across several core therapeutic areas including oncology, immunology, neuroscience, cardiovascular, and renal diseases. Following the strategic spin-off of its Sandoz generics business in 2023, the company has focused exclusively on high-value innovative medicines. Novartis is a pioneer in advanced therapy platforms, maintaining a dominant position in radioligand therapy, cell and gene therapies, and RNA-based therapeutics. Its commercial portfolio features high-growth products such as Entresto, Cosentyx, and Kesimpta, alongside breakthrough treatments like the CAR-T therapy Kymriah and the gene therapy Zolgensma. The company maintains a robust R&D engine through Novartis Biomedical Research and a deep clinical pipeline with over 100 projects in development.